TITLE

Dapagliflozin (BMS-512148), a Selective Inhibitor of the Sodium-Glucose Uptake Transporter 2 (SGLT2), Reduces Fasting Serum Glucose and Glucose Excursion in Type 2 Diabetes Mellitus Patients Over 14 Days

AUTHOR(S)
Komoroski, Bernard; Brenner, Erik; Li, Li; Vachharajani, Nimish; Kornhauser, David
PUB. DATE
June 2007
SOURCE
Diabetes;Jun2007 Supplement 1, Vol. 56, pA49
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the results of a clinical study examining the ability of dapagliflozin to reduce fasting serum glucose and glucose excursion in patients with type 2 diabetes mellitus (T2DM) over 14 days. It mentions that dapagliflozin is a selective inhibitor of the sodium-glucose uptake transporter 2 used as treatment for T2DM. It states that 45.2, 75.3 and 81.3 were the mean amount of glucose eliminated in the urine following the first dose of 5, 25 and 100 mg, respectively.
ACCESSION #
25820505

 

Related Articles

  • HYPOGLYCEMIC AND ANTIHYPERGLYCEMIC EFFECTS OF AQUEOUS EXTRACT OF IXERIS GRACILIS DC. ON NORMAL AND ALLOXAN-INDUCED DIABETIC MICE. Syiem, Donkupar; Warjri, Phibangipan // Diabetologia Croatica;2011, Vol. 40 Issue 3, p89 

    The potential blood glucose lowering effects of Ixeris (I.) gracilis (Asteraceae), an edible wild plant found in parts of Meghalaya, India, is reported. Varying doses (250, 450, 650, 850 and 1000 mg/kg body weight) of aqueous extract of the leaves of I. gracilis were administered...

  • Insulin degludec in Phase 3 trials.  // Clinical Cardiology Alert;May2011 Pharmacology, p2 

    The article reports that insulin degludec, an ultralong-acting insulin, is currently undergoing Phase 3 trials, and discusses a study which concluded that insulin degludec provides glycemic control without adverse events (AEs) and may reduce dosing frequency.

  • Insulin degludec in Phase 3 trials.  // Clinical Oncology Alert;May2011 Supplement 2, p2 

    The article reports that insulin degludec, an ultralong-acting insulin, is currently undergoing Phase 3 trials, and discusses a study which concluded that insulin degludec provides glycemic control without adverse events (AEs) and may reduce dosing frequency.

  • Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Musi, Nicolas; Hirshman, Michael F.; Nygren, Jonas; Svanfeldt, Monika; Bavenholm, Peter; Rooyackers, Olav; Zhou, Gaochao; Williamson, Joanne M.; Ljunqvist, Olle; Efendic, Suad; Moller, David E.; Thorell, Anders; Goodyear, Laurie J. // Diabetes;Jul2002, Vol. 51 Issue 7, p2074 

    Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity...

  • ANT! DIABETIC EFFECT OF A CHYRANTHES RUBROFUSCA LEAF EXTRACTS ON ALLOXAN INDUCED DIABETIC RATS.  // Pakistan Journal of Pharmaceutical Sciences;Apr2011, Vol. 24 Issue 2, p193 

    No abstract available.

  • Diabetic control in pregnancy and labour. Watkins, P. J. // Journal of the Royal Society of Medicine;Mar1978, Vol. 71 Issue 3, p202 

    The article presents the means of achieving the benefits of a good diabetic control in pregnancy. Diabetic physician focuses on the maintenance of a high standard of diabetic control throughout the pregnancy to normalize the blood glucose levels through diet with insulin introduction. Diabetic...

  • Your Insulin Therapy.  // American Family Physician;8/1/2004, Vol. 70 Issue 3, p511 

    Presents information on insulin therapy. Kinds of insulin; Symptoms of low blood sugar; Mealtime insulin type and dose.

  • Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy. McCormack, James G.; Westergaard, Niels; Kristiansen, Marit; Brand, Christian L.; Lau, Jesper // Current Pharmaceutical Design;Sep2001, Vol. 7 Issue 14, p1451 

    The inappropriate overproduction of glucose by the liver is one of the key contributors to the hyperglycaemia of the diabetic state, and thus is a logical site of intervention for novel anti-diabetic approaches. Metformin is the only currently marketed anti-hyperglycaemic drug whose action is...

  • Dia-B Tech: ISF402 progress promising but slow.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p23 

    The article presents a study conducted by Monash University, which identifies that the newly invented drug ISF402 could help type 2 diabetes sufferers lower blood glucose levels and enhance the effects of insulin in the U.S. The major advantage of the drug over existing therapies is that ISF is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics